Stock Updates

Today’s Top Gainers in the Market Mylan N.V. (NASDAQ:MYL) from Healthcare

Today’s top gainers include the company Mylan N.V. (NASDAQ:MYL) which is in the industry Drugs – Generic, gaining -0.91% today. In the last week its performance is -9.37%, and -12.33% for the past quarter. Currently, Mylan N.V., MYL has a target price of 56, so today’s gain of -0.91% is a significant step towards its target price. The GAP today is therefore -0.36%.

Mylan N.V. (NASDAQ:MYL), has a market cap of 20577.94, and is based in USA. Insider ownership is at 0.50%, and institutional ownership is 64.50%.

At the current price of 38.12, it has a dividend yield of *TBA, and its target price is 56. This is with a profit margin of 8.10%, and total debt/equity of 1.31. Mylan N.V. (NASDAQ:MYL) has a P/E of 24.23, as well as a forward P/E of 6.63.

With a current EPS of 1.57, and a forecasted EPS growth for next year at 15.96%,Mylan N.V. (NASDAQ:MYL) has had a EPS growth for the past five years at 20.20%. For the next five years EPS growth is projected to be 13.08%.

Performance for the year is -7.94%. Since its IPO date on 12/18/1987, the total performance to date is -29.50%.

Volume today for Mylan N.V. (NASDAQ:MYL), is 7254100, while its average volume is 5967.76. Whilst the total gain today was -0.91%, it did have a day high of -24.37%.

Volatility for this week has been at 3.25%, and 2.72% for the month. The 52-week low for Mylan N.V., MYL has been 1.41%, while the 52-week-high has reached -31.33%.

Looking at its return of investments, which is 8.20%, and its return on assets is 3.40%. Mylan N.V. (NASDAQ:MYL) has an operating margin of 15.70%. With a sales growth of 8.00% quarter over quarter. Bearing in mind that Mylan N.V., MYL is in the sector Healthcare, its long-term debt/equity is 1.24, and has a current ratio of 3.2 and 2.6 for quick ratio.

So what is the value of Mylan N.V.? Well its PEG is 1.85, and the P/S is 2.07, along with a P/B of 1.86. Meanwhile it has a p/cash of 3.23.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Peter Clarke

Leave a Comment